|
David L. Urdal, Ph.D. is currently Senior Vice President and Chief Scientific Officer of Dendreon Corporation, a Seattle-based biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer. Dr. Urdal has served as Dendreon�s Chief Scientific Officer since joining the company in 1995. Prior to that time, he held various positions with Immunex Corporation, including President of Immunex Manufacturing Corporation, Vice President and Director of Development, and head of the departments of biochemistry and membrane biochemistry. Dr. Urdal received an M.S. in Public Health and a Ph.D. in Biochemical Oncology from the University of Washington. | 